Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Jueling Yang
Safety, Pharmacokinetics and Pharmacodynamics of Single Doses of Rivaroxaban – An Oral, Direct Factor Xa Inhibitor – In Elderly Chinese Subjects
Thrombosis and Haemostasis
Hematology
Related publications
Rivaroxaban: An Oral Direct Inhibitor of Factor Xa
American Journal of Health-System Pharmacy
Medicine
Health Policy
Pharmacology
Pharmacy
Pharmacokinetics, Pharmacodynamics, Tolerability and Safety of Single Doses of Bivalirudin in Healthy Chinese Subjects
Biological and Pharmaceutical Bulletin
Medicine
Pharmacology
Pharmaceutical Science
Effect of Famotidine on the Pharmacokinetics of Apixaban, an Oral Direct Factor Xa Inhibitor
Clinical Pharmacology: Advances and Applications
Pharmacology
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of Empagliflozin, a Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor, in Healthy Japanese Subjects
Drug Metabolism and Pharmacokinetics
Pharmacology
Pharmaceutical Science
Pharmacokinetics and Safety of Enasidenib Following Single Oral Doses in Japanese and Caucasian Subjects
Pharmacology Research and Perspectives
Toxicology
Neurology
Pharmaceutics
Pharmacology
The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of CH4987655 in Healthy Volunteers: Target Suppression Using a Biomarker
Clinical Cancer Research
Cancer Research
Oncology
Treatment of Proximal Deep-Vein Thrombosis With the Oral Direct Factor Xa Inhibitor Rivaroxaban (BAY 59-7939): The ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) Study
Circulation
Cardiovascular Medicine
Physiology
Cardiology
Safety, Pharmacokinetics, and Pharmacodynamics of the Autotaxin Inhibitor GLPG1690 in Healthy Subjects: Phase 1 Randomized Trials
Journal of Clinical Pharmacology
Pharmacology
A Randomized Direct Comparison of the Pharmacokinetics and Pharmacodynamics of Apixaban and Rivaroxaban [Corrigendum]
Clinical Pharmacology: Advances and Applications
Pharmacology
